Directive 2003/63 - Amendment of Directive 2001/83/EC on the EC code relating to medicinal products for human use - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human useLegal instrument | Directive |
---|---|
Number legal act | Directive 2003/63 |
CELEX number i | 32003L0063 |
Document | 25-06-2003 |
---|---|
Publication in Official Journal | 27-06-2003; Special edition in Slovak: Chapter 13 Volume 031,Special edition in Czech: Chapter 13 Volume 031,Special edition in Croatian: Chapter 13 Volume 058,Special edition in Maltese: Chapter 13 Volume 031,Special edition in Latvian: Chapter 13 Volume 031,Special edition in Bulgarian: Chapter 13 Volume 039,Special edition in Polish: Chapter 13 Volume 031,Special edition in Romanian: Chapter 13 Volume 039,Special edition in Estonian: Chapter 13 Volume 031,Special edition in Hungarian: Chapter 13 Volume 031,Special edition in Lithuanian: Chapter 13 Volume 031,OJ L 159, 27.6.2003,Special edition in Slovenian: Chapter 13 Volume 031 |
Effect | 30-06-2003; Entry into force Date pub. + 3 See Art 3 01-07-2003; Application See Art 2 |
End of validity | 31-12-9999 |
Transposition | 31-10-2003; At the latest See Art 2 |
|
Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance)
Official Journal L 159 , 27/06/2003 P. 0046 - 0094
Commission directive 2003/63/EC
of 25 June 2003
amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating medicinal products for human use(1), as last amended by Directive 2002/98/EC(2), and in particular Article 120 thereof,
Whereas:
-
(1)Every medicinal product for human use that is to be placed on the European Community market must be granted a marketing authorisation delivered by a competent authority. With the view to obtaining a marketing authorisation, an application dossier containing particulars and documents relating to the results of tests and trials carried out on this medicinal product must be submitted.
-
(2)The detailed scientific and technical requirements of Annex I to Directive 2001/83/EC need to be adapted to take account of scientific and technical progress and in particular of a large set of new requirements resulting from recent legislation. The presentation and content of the marketing authorisation application dossier have to be improved in order to facilitate the assessment and the better use of certain parts of the dossier which are common to several medicinal products.
-
(3)Within the framework of the International Conference on Harmonisation (ICH) a consensus was reached in 2000 to provide a harmonised format and terminology for a Common Technical Document through which a homogeneous organisation and presentation of a marketing authorisation application dossier for human medicinal products could be achieved. Standardised marketing authorisation dossier requirements should therefore be introduced in order to implement the Common Technical Document without delay.
-
(4)The standardised marketing authorisation dossier requirements (harmonised format) should be applicable to any type of medicinal product for human use, regardless of the procedure for the granting of the marketing authorisation. Some medicinal products present, however, such specific features that all the requirements cannot be fulfilled. To take account of these particular situations, a simplified dossier presentation should be provided for.
-
(5)The safety of biological medicinal products relies on rigorous control of their starting materials. Requirements for the suitability of human donors and the testing of donations of starting materials for plasma-derived medicinal products are laid down by Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. Article 109 of Directive 2001/83/EC has been amended. Plasma-derived medicinal products per se are biological medicinal products, the manufacture of which is based on the careful handling of human plasma as a starting material. To take account of the fact that the same plasma material is used in most cases for several medicinal products and, as a result, that a substantial part of the marketing authorisation dossier may be common to a great number of other dossiers for totally different plasma-derived medicinal products, it is appropriate to establish a new system aimed at simplifying procedures for both the approval of and subsequent changes to human plasma-derived medicinal products. To this end the concept...
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.